EUVIMEDEUVIMED entdecken
Open Access

GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024

Anjel Vahratian, Antonia Warren

· 2025

DOI: 10.15620/cdc/174616 ↗

Kurz gefasst

Fachartikel, 2025. Verfasst von Anjel Vahratian und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Hypoglycemic Agents, Diabetes Mellitus. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This report describes the percentage of adults with diagnosed diabetes who were taking an injectable glucagon-like peptide-1 (GLP-1) receptor agonist at the time of the interview by selected characteristics based on data from the 2024 National Health Interview Survey (NHIS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Hypoglycemic AgentsDiabetes MellitusHumansUnited StatesMiddle AgedAdultMaleFemaleAgedAdolescentYoung AdultInjectionsGlucagon-Like Peptide-1 Receptor AgonistsHealth Surveys

Stichwörter der Autor:innen

National Health Interview Survey (NHIS)dulaglutideglycemic controlincretin mimeticssemaglutide

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Zitieren

APA

Vahratian, A., & Warren, A. (2025). GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024. . https://doi.org/10.15620/cdc/174616

Vancouver

Vahratian A, Warren A. GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024. 2025. doi:10.15620/cdc/174616

BibTeX
@article{Vahratian2025,
  author = {Vahratian, Anjel and Warren, Antonia},
  title = {GLP-1 Injectable Use Among Adults with Diagnosed Diabetes: United States, 2024},
  year = {2025},
  doi = {10.15620/cdc/174616}
}
Kostenlos starten →